Search Medical Condition
Please enter condition
Please choose location from dropdown

Draguignan, France Clinical Trials

A listing of Draguignan, France clinical trials actively recruiting patients volunteers.

RESULTS

Found (11) clinical trials

Second-line Treatment in Patients With Small Cell Lung Cancer (SCLC)

Determined treatment efficacy and tolerability of second-line treatment in patients with small cell lung cancer comparing oral combinaison chemotherapy with intravenous combination chemotherapy.

Phase

0.0 miles

Learn More »

An Efficacy Study of Pomalidomide in Patient With Multiple Myeloma in Routine Clinical Practice

This study, a national, multicenter, observational, ambispective, non-interventional study, will be conducted in French hospitals prescribing pomalidomide and already participating in the ongoing Imnovid registry. This study will add to the registry. Indeed, pomalidomide-prescribing physicians and pharmacists dispensing pomalidomide have to enter into the Imnovid registry all patients who have ...

Phase N/A

0.0 miles

Learn More »

Addition of Aromatase at the Navelbine in Pretreated Metastatic Breast Cancer.

The CHEOPS study aims to confirm the clinical benefit of a combination of an anti-aromatase and metronomic chemotherapy treatment that would have the theoretical advantage of being well tolerated and more effective than chemotherapy alone even after an anti-aromatase therapy.

Phase

0.0 miles

Learn More »

Phase II Trial of Carboplatin 5-FU and Cetuximab in Elderly Fit (no Frailty) Patients With Recurrent/Metastatic HNSCC

The aim of the trial is to evaluate the clinical benefit (efficacy, safety, preservation of autonomy) of cetuximab-carboplatin-5FU combination as first line treatment of recurrent or metastatic head and neck squamous cell carcinoma in patients over 70 years without frailty (after geriatric assessment).

Phase

0.0 miles

Learn More »

Therapeutic Strategies in Patients With Non-squamous Non-small Cell Lung Cancer With Brain Metastases

This is a trial comparing two strategies with the aim to determine the best place for cerebral radiotherapy (initially or only systematic progression). Arm A: Initial cerebral radiotherapy and chemotherapy, standard arm Arm B: Chemotherapy and Radiotherapy brain if clinical or radiological cerebral progression , experimental arm (The chemotherapy treatments ...

Phase

0.0 miles

Learn More »

End Of Life in the Critically Ill patiEnt

More than 20% of deaths occur in hospital after a stay in intensive care units; up to half of them happens as result of a treatment limitation. Ensuring end-of-life quality is important, not only because is a moral duty of all caregivers, but also to prevent negative effects in close ...

Phase N/A

0.0 miles

Learn More »

Analysis of Factors Related to Occurrence of Serious Adverse Events During Nursing in Intensive Care Units

Patients who are hospitalized in intensive care unit (ICU) require basic nursing care to improve patient hygiene, to promote comfort, to prevent pressure ulcer, and foot or hand's retractations. Those nursing cares require mobilization very frequently which expose critically ill patients to occurrence of serious adverse events (SAE) such as ...

Phase N/A

0.0 miles

Learn More »

Treatment After Irinotecan-based Frontline Therapy: Maintenance With Erbitux (in Patients wtRAS mCRC)

National multicentric phase II trial evaluating whether single agent cetuximab is effective as maintenance therapy after 8 cycles of first line FOLFIRI plus cetuximab in mCRC patients with KRAS and NRAS wild-type genes, assessed by progression-free survival at 6 months after start of maintenance therapy.

Phase

1.85 miles

Learn More »

Prevalence of Fabry's Disease in a Population of Patients With Chronic Pain

Fabry disease (FD) is a rare X-linked multisytemic lysosomal disorder caused by alpha-galactosidase deficiency. Globotriaosylcramide (Gb3) deposits are observed in almost all tissues examined. Signs of the disease appear earlier and are more severe in affected males than in females. Myocardiopathy, renal failure and neurological signs including chronic pain and ...

Phase N/A

1.85 miles

Learn More »